455 related articles for article (PubMed ID: 10878819)
41. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
42. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
43. Genetic clues to the pathogenesis of Parkinson's disease.
Vila M; Przedborski S
Nat Med; 2004 Jul; 10 Suppl():S58-62. PubMed ID: 15272270
[TBL] [Abstract][Full Text] [Related]
44. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
Cabin DE; Gispert-Sanchez S; Murphy D; Auburger G; Myers RR; Nussbaum RL
Neurobiol Aging; 2005 Jan; 26(1):25-35. PubMed ID: 15585343
[TBL] [Abstract][Full Text] [Related]
45. Parkinson's disease and other alpha-synucleinopathies.
Goedert M
Clin Chem Lab Med; 2001 Apr; 39(4):308-12. PubMed ID: 11388653
[TBL] [Abstract][Full Text] [Related]
46. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
47. Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress.
Jakobsen LD; Jensen PH
Methods Mol Biol; 2003; 232():57-66. PubMed ID: 12840539
[No Abstract] [Full Text] [Related]
48. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
[TBL] [Abstract][Full Text] [Related]
49. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
50. Genetics of movement disorders: an abbreviated overview.
Thyagarajan D
Stereotact Funct Neurosurg; 2001; 77(1-4):48-60. PubMed ID: 12378057
[TBL] [Abstract][Full Text] [Related]
51. alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?
Lee SJ
Antioxid Redox Signal; 2003 Jun; 5(3):337-48. PubMed ID: 12880487
[TBL] [Abstract][Full Text] [Related]
52. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
53. Genetic and environmental factors in the cause of Parkinson's disease.
Warner TT; Schapira AH
Ann Neurol; 2003; 53 Suppl 3():S16-23; discussion S23-5. PubMed ID: 12666095
[TBL] [Abstract][Full Text] [Related]
54. Targeting alpha-synuclein in Parkinson's disease.
Kapurniotu A
Chem Biol; 2004 Nov; 11(11):1476-8. PubMed ID: 15555995
[TBL] [Abstract][Full Text] [Related]
55. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.
Mamah CE; Lesnick TG; Lincoln SJ; Strain KJ; de Andrade M; Bower JH; Ahlskog JE; Rocca WA; Farrer MJ; Maraganore DM
Ann Neurol; 2005 Mar; 57(3):439-43. PubMed ID: 15732111
[TBL] [Abstract][Full Text] [Related]
56. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
57. Recent advances on alpha-synuclein cell biology: functions and dysfunctions.
Alves da Costa C
Curr Mol Med; 2003 Feb; 3(1):17-24. PubMed ID: 12558071
[TBL] [Abstract][Full Text] [Related]
58. Neurodegenerative disease: amyloid pores from pathogenic mutations.
Lashuel HA; Hartley D; Petre BM; Walz T; Lansbury PT
Nature; 2002 Jul; 418(6895):291. PubMed ID: 12124613
[TBL] [Abstract][Full Text] [Related]
59. Experimental models of Parkinson's disease.
Beal MF
Nat Rev Neurosci; 2001 May; 2(5):325-34. PubMed ID: 11331916
[TBL] [Abstract][Full Text] [Related]
60. Are ubiquitination pathways central to Parkinson's disease?
Giasson BI; Lee VM
Cell; 2003 Jul; 114(1):1-8. PubMed ID: 12859888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
